Fernando J. Martinez
Cornell University
Publications 976
#1Courtney Crim (RTP: Research Triangle Park)H-Index: 33
#2Julie A. Anderson (GSK: GlaxoSmithKline)H-Index: 28
Last.Robert D. Brook (UM: University of Michigan)H-Index: 55
view all 10 authors...
#1W. ZhangH-Index: 2
#2Michelle C. RiceH-Index: 1
Last.Mary E. ChoiH-Index: 25
view all 26 authors...
#1Ganesh Raghu (UW: University of Washington)H-Index: 70
#2Brett Ley (UCSF: University of California, San Francisco)H-Index: 19
Last.Fernando J. Martinez (Cornell University)H-Index: 111
view all 21 authors...
In this retrospective study of a randomised trial of simtuzumab in idiopathic pulmonary fibrosis (IPF), prodromal decline in forced vital capacity (FVC) was significantly associated with increased risk of mortality, respiratory and all-cause hospitalisations, and categorical disease progression. Predictive modelling of progression-free survival event risk was used to assess the effect of population enrichment for patients at risk of rapid progression of IPF; C-index values were 0.64 (death), 0.6...
#1Barbara P. Yawn (UMN: University of Minnesota)H-Index: 50
#2Fernando J. Martinez (NewYork–Presbyterian Hospital)H-Index: 111
1 CitationsSource
#1Barbara P. Yawn (UMN: University of Minnesota)H-Index: 50
#2Fernando J. Martinez (NewYork–Presbyterian Hospital)H-Index: 111
#1Dave SinghH-Index: 50
#2Gerald J. Criner (TU: Temple University)H-Index: 13
Last.David A. LipsonH-Index: 20
view all 13 authors...
Introduction IMPACT etude multicentrique, en double aveugle, randomisee de 52 semaines a compare Furoate de Fluticasone/Umeclidinium/Vilanterol (FF/UMEC/VI) 100/62,5/25 μg a Furoate de Fluticasone/Vilanterol (FF/VI) 100/25 μg et Umeclidinium/Vilanterol (UMEC/VI) 62,5/25 μg chez des patients ≥ 40 ans avec une BPCO symptomatique et des antecedents d’exacerbations (n = 10 355). Le critere d’evaluation principal etait le taux annuel d’exacerbations moderees/severes (M/S). Presentation ci-apres des a...
Introduction Dans l’etude randomisee en double aveugle KRONOS ( NCT02497001 , Ferguson et al. Lancet Respir Med 2018 ;6 :747–58), la triple therapie par budesonide/glycopyrrolate/formoterol fumarate (BGF MDI) en inhalateur-doseur (MDI), a demontre une amelioration de la fonction pulmonaire et une diminution de la frequence des exacerbations comparee aux bitherapies chez les patients atteints de BPCO moderee a tres severe. Nous avons effectue une analyse du sous-groupe de patients de cette etude ...
#1Laura M. Paulin (Dartmouth College)H-Index: 7
#2Amanda J. Gassett (UW: University of Washington)H-Index: 6
Last.Nadia N. Hansel (Johns Hopkins University)H-Index: 41
view all 24 authors...
Importance Few studies have investigated the association of long-term ambient ozone exposures with respiratory morbidity among individuals with a heavy smoking history. Objective To investigate the association of historical ozone exposure with risk of chronic obstructive pulmonary disease (COPD), computed tomography (CT) scan measures of respiratory disease, patient-reported outcomes, disease severity, and exacerbations in smokers with or at risk for COPD. Design, Setting, and Participants This ...
1 CitationsSource